Melanotan II vs Bremelanotide
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
Melanotan-II (MT-II) is described in the provided literature as a lactam-bridged cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been evaluated in vitro as a “superpotent” melanotropic peptide, studied in a pilot phase-I clinical setting, investigated for diet-induced neurobehavioral changes in zebrafish, used as a starting point for peptide engineering to obtain different melanocortin receptor agonist profiles, and discussed in relation to renal infarction reports and preformulation properties.
Bremelanotide is a synthetic cyclic peptide analogue described as a melanocortin receptor agonist. Research reported that it has been studied for hypoactive sexual desire disorder (HSDD) and that it received FDA approval in the USA for acquired, generalized HSDD in premenopausal women. Source articles also summarize development milestones and clinical trial evidence (including phase 2 and phase 3 studies). (PMIDs: 31369224, 31893927, 36809187, 31599840)
| Melanotan II | Bremelanotide | |
|---|---|---|
| Family | Melanocortin agonists | Melanocortin agonists |
| Research goals | Skin, hair & pigmentation, Sexual & reproductive | Sexual & reproductive |
| Amino acids | — | — |
| Molecular formula | C50H69N15O9 | C50H68N14O10 |
| Molecular weight | 1024.2 g/mol | 1025.2 g/mol |
| CAS number | 121062-08-6 | 189691-06-3 |
| Approx. half-life | — | — |
| Regulatory status | Research only | FDA-approved drug |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 9 | 10 |